Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.35 |
| ▸ | ABCG2 | Q9UNQ0 | 4/20 | 0.33 |
| ▸ | GSK3B | P49841 | 3/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.32 |
| ▸ | GSK3A | P49840 | 2/20 | 0.32 |
| ▸ | SGK2 | Q9HBY8 | 2/20 | 0.32 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.32 |
| ▸ | CLK2 | P49760 | 1/20 | 0.32 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.32 |
| ▸ | PRKG1 | Q13976 | 1/20 | 0.32 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.32 |
| ▸ | CSNK1G1 | Q9HCP0 | 1/20 | 0.32 |
| ▸ | CSNK1G3 | Q9Y6M4 | 1/20 | 0.32 |
| ▸ | GBA1 | P04062 | 4/20 | 0.31 |
| ▸ | GLA | P06280 | 2/20 | 0.31 |
| ▸ | PLK4 | O00444 | 1/20 | 0.31 |
| ▸ | AURKA | O14965 | 1/20 | 0.31 |
| ▸ | CHUK | O15111 | 1/20 | 0.31 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24974628 | 0.88 | GSK3B (0.36) | EGLN1ABCG2GSK3BROCK2MAPK1 | |
| SCHEMBL21151185 | 0.82 | HDAC1 (0.41) | ABCG2AKT1FABP7CDC7 | |
| SCHEMBL21151320 | 0.78 | TACR1 (0.37) | EGLN1ABCG2GSK3BROCK2MAPK1 | |
| SCHEMBL24974685 | 0.76 | KMT2A (0.37) | ROCK2MAPK1RPS6KB1CDK2 | |
| SCHEMBL21150836 | 0.76 | DYRK3 (0.33) | GSK3BROCK2MAPK1GSK3ASGK2 | |
| SCHEMBL21151212 | 0.72 | MGLL (0.35) | ABCG2MAPK1FABP7 | |
| SCHEMBL21151322 | 0.72 | DRD2 (0.31) | — | |
| SCHEMBL24974686 | 0.71 | TACR1 (0.35) | GSK3BROCK2MAPK1GSK3ASGK2 | |
| SCHEMBL24974635 | 0.70 | HDAC3 (0.43) | ABCG2GSK3BROCK2MAPK1SGK2 | |
| SCHEMBL18373050 | 0.69 | SRC (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11572370-B2 | CD16A binding agents and uses thereof | BIOHAVEN THERAPEUTICS LTD. (US) | 2023-02-07 | — | — | US | disclosed |
| WO-2019136442-A1 | CD16A BINDING AGENTS AND USES THEREOF | KLEO PHARMACEUTICALS, INC. (US) | 2019-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11572370-B2 | CD16A binding agents and uses thereof | FCGR1A, FCGR2A, FCGR3B | EGLN1 4635/4885ABCG2 771/4885GSK3B 4026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.